Merck & Co, INC Form 4 insider transactions

Director Mary Ellen Coe reports acquisition of phantom stock units convertible to common stock in a recent transaction.

Merck & Co., Inc. finalizes the acquisition of Harpoon Therapeutics through a merger, resulting in Merck becoming the direct beneficial owner of 100% of Harpoon's common stock.